Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times
Ritesh Presswala

Lupin shares in focus after USFDA nod for drug to treat excessive daytime sleepiness

Lupin shares are likely to remain in focus in Tuesday’s trading session after the pharmaceutical major received final approval from the US Food and Drug Administration (USFDA) for its generic version of Pitolisant Tablets, a drug used to treat excessive daytime sleepiness.

Lupin announced that the USFDA has granted final approval for its Abbreviated New Drug Application (ANDA) covering Pitolisant Tablets in 4.45 mg and 17.8 mg strengths.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.